HIVMA Policy Statements

Policy Statements

• Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association link

  January 2025

• Position of IDSA and HIVMA on Team-based Infectious Diseases Care and the Roles of Advanced Practice Providers and Clinical Pharmacists link

  May 2024 IDSA and HIVMA position supporting APPs and clinical pharmacists working at the top of their license and training to promote equitable access to ID care.

• Protecting Patient Autonomy and the Provider-Patient Relationship link

  Sept 2022 IDSA and HIVMA position opposing government interference in the patient-health care provider relationship.

• Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association link

  August 2022 Ten principles for policy reforms to end the HIV epidemic in the U.S.

• Innovations in HIV Care Delivery During the COVID-19 Pandemic: Policies to Strengthen the Ending the Epidemic Initiative link

  A policy paper of IDSA and HIVMA.

• Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda Sept 2020 link

  Policy recommendations for reducing infections, drug overdoses and deaths due to the overlapping epidemics of drug use and infectious Diseases.

• IDSA, HIVMA and PIDS Policy Statement on the Medicaid Program, Public Health and Access to HIV Care pdf

  June 2017  A paper highlighting policies to sustain access to the Medicaid program.

• IDSA, HIVMA and SIDP Policy Statement on the Evaluation of Safe Consumption Sites in the U.S. to Reduce Overdose Deaths and Prevent the Spread of Infections as Part of a Comprehensive Response to the Opioid Epidemic link

  March 2017  The Infectious Diseases Society of America (IDSA), the HIV Medicine Association (HIVMA) and the Society of Infectious Diseases Pharmacists (SIDP) strongly support a public health approach to addressing the opioid epidemic to reduce the spread of infections and to engage individuals who inject drugs in substance use treatment and other healthcare services.

• IDSA, HIVMA and PIDS Policy Statement Opposing Anti-LBGT Laws pdf

  October 2016 The Infectious Diseases Society of America (IDSA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS) oppose laws and policies that discriminate against Lesbian, Gay, Bisexual and Transgender (LGBT) individuals.

• IDSA and HIVMA Position on the Criminalization of HIV, Sexually Transmitted Infections and Other Communicable Diseases pdf

  March 2015 Criminalization is not an effective strategy for reducing transmission of infectious diseases. IDSA and HIVMA urge state policymakers to promote public health by revising statutes that criminalize transmission of diseases, such as HIV infection, viral hepatitis and other communicable diseases.

• Policy Statement on Syringe Access and Paraphernalia Laws pdf

  April 2014 Because transmission occurs through the sharing or re-use of infected paraphernalia, access to uninfected injection equipment is a key part of infection prevention programs. Currently, Congress prohibits local health authorities from using federal funds for syringe exchange programs (SEPs)

• Solutions Needed to Address HIV Public Health Crisis in the US pdf

  January 2012 HIVMA calls on policymakers, industry partners, philanthropists, advocates, providers, and HIV professional organizations to collaborate to identify solutions to address the HIV public health crisis in the U.S.

• HIVMA, Ryan White Policy Paper Identifies Key Components of Effective Care link

  October 2011 HIVMA and the Ryan White Medical Providers Coalition (RWMPC) developed a paper describing the ideal HIV care model and calling for innovative financing and continued public health funding to support this care and expand it.